Activated Charcoal Antimony Trisulfide Apis Mellif
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Antimony Trisulfide Apis Mellif
- Homeopathic 27-Component Preparation: No Repurposing Prediction Available
Homeopathic 27-Component Preparation: No Repurposing Prediction Available
One-Sentence Summary
This product is a 27-ingredient homeopathic combination preparation containing botanical, mineral, and biological substances (including Apis mellifera, Arsenic trioxide, Sepia officinalis juice, and Lycopodium clavatum spore, among others), with no registered indications, no established conventional pharmacological profile, and no DrugBank identifier. The TxGNN model did not generate any repurposing prediction for this compound, and the current evidence pack contains insufficient data to support a drug repurposing evaluation. As a result, no evidence level can be assigned, and this candidate cannot proceed beyond the initial screening stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A – No prediction generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This submission contains 27 declared active ingredients spanning disparate pharmacological and biological categories:
- Conventional toxicological substances: Arsenic trioxide, Nitric acid, Sulfuric acid, Barium carbonate, Antimony trisulfide, Tellurium
- Biological venoms: Apis mellifera (honeybee), Lachesis muta venom (lancehead pit viper)
- Botanical extracts: Bryonia alba root, Daphne mezereum bark, Lycopodium clavatum spore, Phytolacca americana root, Sanicula europaea leaf, Solanum dulcamara top, Thuja occidentalis leafy twig
- Biological sources: Candida albicans, Saccharomyces cerevisiae, Sepia officinalis juice
- Minerals and elements: Activated charcoal, Copper, Graphite, Oyster shell calcium carbonate, Phosphorus, Potassium carbonate, Silicon dioxide, Sulfur, Zinc
The combination pattern is characteristic of a classical homeopathic polypharmacy preparation. Each ingredient corresponds to a recognized homeopathic materia medica entry, and the preparation as a whole likely contains each substance at high dilution consistent with homeopathic practice.
The TxGNN knowledge graph operates on single-entity DrugBank-mapped compounds. Because this preparation:
- Has no DrugBank ID assigned to the combination
- Presents as a mixture rather than a single molecular entity
- Has no conventional pharmacological MOA on record
…it falls outside the operational scope of TxGNN’s repurposing algorithm, and no prediction was generated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
This product has no US NDA or approved authorization on record. It is not marketed in the United States.
Safety Considerations
Please refer to the package insert for safety information.
Special note regarding ingredient toxicology: Several declared ingredients carry inherent toxicological concern at conventional doses, including arsenic trioxide (cardiotoxic, genotoxic), nitric acid, sulfuric acid, barium carbonate (neurotoxic), antimony trisulfide, and lachesis muta venom (hemotoxic). Arsenic trioxide at therapeutic (non-homeopathic) doses is a regulated antineoplastic agent requiring strict cardiac monitoring. The actual risk profile of this preparation is indeterminate without quantitative dose information per ingredient.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is a homeopathic polypharmacy preparation with no DrugBank mapping, no registered indication, no TxGNN repurposing prediction, and no retrievable safety or efficacy data in the current evidence pack. There is no actionable scientific basis to proceed with a formal repurposing evaluation at this stage.
To proceed, the following is needed:
- Clarify the regulatory and scientific framework: Is the intent to evaluate this as a conventional drug repurposing candidate, or as a homeopathic product subject to a different evidence standard?
- Identify the primary active ingredient (if any single component is the intended therapeutic agent) and re-submit as a single-entity query to TxGNN
- Obtain quantitative dose information for each of the 27 components to enable toxicological risk assessment
- Locate or obtain the product package insert to document any registered indication, preparation method, and intended use
- Conduct a targeted PubMed search for the individual high-interest components (e.g., arsenic trioxide, Thuja occidentalis) separately if repurposing evaluation is intended at the ingredient level
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.